This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $298,948 to Sherlock Biosciences, Inc. to develop a power-free molecular diagnostic device for detecting Chlamydia trachomatis and Neisseria gonorrhoeae, two sexually transmitted infections. The project aims to create an accurate, transportable, easy-to-use, and inexpensive diagnostic test that can be used by consumers at home rather than only in clinical settings. The key products to be delivered include optimizing sample preparation techniques, establishing reagent formulations, and assessing the sensitivity, specificity, and failure rate of the prototype device. This work will refine the accuracy of the diagnostic platform for potential validation and extension to other sexually transmitted infections in a future Phase 2 project.